StockData
Halozyme Therapeutics, Inc. logo

Halozyme Therapeutics, Inc. (HALO) stock

HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3037% above fair value
$95.80−0.17 (-0.18%)

Close on Nov 18, 2026Market cap $10.87BP/E 28.3Yield –

Halozyme Therapeutics total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Halozyme Therapeutics's total debt was $2.15B at Jun 30, 2026. For fiscal 2025 it was $2.14B, up 42.3% from the year before. Over ten years it grew 45.7% a year on average. The highest annual figure on record is $2.14B in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.14B+42.3%
FY2024Dec 31, 2024$1.51B+0.4%
FY2023Dec 31, 2023$1.50B-0.5%
FY2022Dec 31, 2022$1.51B+71.8%
FY2021Dec 31, 2021$876.67M+120.7%
FY2020Dec 31, 2020$397.23M-1.3%
FY2019Dec 31, 2019$402.59M+218.6%
FY2018Dec 31, 2018$126.38M-37.5%
FY2017Dec 31, 2017$202.35M-6.6%
FY2016Dec 31, 2016$216.62M+334.7%
FY2015Dec 31, 2015$49.83M-0.1%
FY2014Dec 31, 2014$49.86M+0.2%
FY2013Dec 31, 2013$49.77M+67.8%
FY2012Dec 31, 2012$29.66M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.15B+42.2%
Q1 FY2026Mar 31, 2026$2.14B+42.3%
Q4 FY2025Dec 31, 2025$2.14B+42.3%
Q3 FY2025Sep 30, 2025$1.51B+0.4%
Q2 FY2025Jun 30, 2025$1.51B+0.4%
Q1 FY2025Mar 31, 2025$1.51B+0.4%
Q4 FY2024Dec 31, 2024$1.51B+0.4%
Q3 FY2024Sep 30, 2024$1.50B+0.4%
Q2 FY2024Jun 30, 2024$1.50B+0.4%
Q1 FY2024Mar 31, 2024$1.50B+0.4%
Q4 FY2023Dec 31, 2023$1.50B-0.5%
Q3 FY2023Sep 30, 2023$1.50B-0.5%
Q2 FY2023Jun 30, 2023$1.50B+1410.4%
Q1 FY2023Mar 31, 2023$1.49B+1568.8%
Q4 FY2022Dec 31, 2022$1.51B+71.8%
Q3 FY2022Sep 30, 2022$1.50B+1585.7%
Q2 FY2022Jun 30, 2022$99.05M+11.1%
Q1 FY2022Mar 31, 2022$89.55M+0.6%
Q4 FY2021Dec 31, 2021$876.67M+120.7%
Q3 FY2021Sep 30, 2021$89.25M–
Q2 FY2021Jun 30, 2021$89.17M–
Q1 FY2021Mar 31, 2021$89.04M+3014.4%
Q4 FY2020Dec 31, 2020$397.23M-1.3%
Q3 FY2020Sep 30, 2020$0-100.0%
Q2 FY2020Jun 30, 2020$0-100.0%
Q1 FY2020Mar 31, 2020$2.86M-96.7%
Q4 FY2019Dec 31, 2019$402.59M+218.6%
Q3 FY2019Sep 30, 2019$54.54M-38.4%
Q2 FY2019Jun 30, 2019$70.88M-18.5%
Q1 FY2019Mar 31, 2019$86.66M+5.1%
Q4 FY2018Dec 31, 2018$126.38M-37.5%
Q3 FY2018Sep 30, 2018$88.52M+44.1%
Q2 FY2018Jun 30, 2018$86.97M+91.1%
Q1 FY2018Mar 31, 2018$82.46M+178.6%
Q4 FY2017Dec 31, 2017$202.35M-6.6%
Q3 FY2017Sep 30, 2017$61.43M+395.7%
Q2 FY2017Jun 30, 2017$45.52M–
Q1 FY2017Mar 31, 2017$29.60M–
Q4 FY2016Dec 31, 2016$216.62M–
Q3 FY2016Sep 30, 2016$12.39M–

More Halozyme Therapeutics figures

See a number that looks wrong?